Progression of Parkinson’s disease slowed by antibody drug.

PARKINSON'S disease; DEEP brain stimulation; DRUGS; RAPID eye movement sleep; SUBTHALAMIC nucleus

A recent study has found that a drug called prasinezumab may slow the progression of Parkinson's disease in individuals with advanced forms of the condition. The drug targets the build-up of a protein called alpha-synuclein in the brain, which is believed to be the underlying cause of Parkinson's. The study showed that prasinezumab was more effective in individuals with more severe Parkinson's symptoms. However, the study did not assess whether the drug actually cleared the protein from the brain, and longer-term data is needed to determine its safety and efficacy. [Extracted from the article]

Copyright of New Scientist is the property of New Scientist Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)